It's been a banner year so far for Palvella Therapeutics Inc. (PVLA), which recently debuted on the Nasdaq, with its share price soaring by as much as 117% year-to-date.
This clinical-stage biopharmaceutical company is exclusively focused on developing transformational therapies for rare diseases with no FDA-approved treatments. Its lead product candidate is QTORIN rapamycin, currently under development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and other serious, functionally debilitating skin diseases driven by the overactivation of the mTOR pathway. The mTOR signaling pathway is a key regulator of cell growth, proliferation, survival, and metabolism.
For comments and feedback: editorial@rttnews.com